(Q36533697)

14 August 2017

1 reference

title

Phosphodiesterase inhibitors in Raynaud's phenomenon (English)

1 reference

14 August 2017

Terri L Levien

1

1 reference

PubMed ID

16835313

14 August 2017

language of work or name

English

0 references

publication date

11 July 2006

1 reference

Annals of Pharmacotherapy

14 August 2017

1 reference

14 August 2017

40

1 reference

14 August 2017

1388-1393

1 reference

14 August 2017

7-8

1 reference

Clinical practice. Raynaud's Phenomenon

14 August 2017

1 reference

Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon

21 January 2018

1 reference

The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia

21 January 2018

1 reference

Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis

21 January 2018

1 reference

Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al.

21 January 2018

1 reference

Severe digital ischaemia treated with phosphodiesterase inhibitors

21 January 2018

1 reference

Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil

21 January 2018

1 reference

Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis

21 January 2018

1 reference

Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis

21 January 2018

1 reference

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H005

1 reference

14 August 2017

1 reference

PubMed ID

16835313